Irish medical technology firm Medtronic has introduced Control Workflow, an evidence-based approach for use with the SynchroMed II intrathecal drug delivery system, in the US.
The Control Workflow intends to address chronic pain without the use of oral opioids. It helps physicians wean patients off oral opioids and treat chronic intractable pain.
SynchroMed II pump and catheter are implanted under the skin to deliver medication into the intrathecal space, allowing clinicians to prescribe reduced doses compared to systemically delivered medications and tailor drug delivery to patient needs.
Medtronic pain pump offers effective pain relief at a fraction of the oral dose with fewer side effects and was demonstrated to reduce or eliminate the use of oral opioids.
According to the company, a retrospective claims analysis showed that 51% of chronic non-malignant pain patients avoided the use of oral opioids after one year on the pump.
Most of the people use oral opioids to treat pain, but there is limited evidence on the effectiveness and benefits of long-term oral opioid therapy.
The Control Workflow, along with Medtronic pain pump, will help in oral opioid elimination and can be used as an alternative to long-term oral opioid therapy for appropriate patients.
The Control Workflow is said to include oral opioid weaning considerations, which can be tailored to individual patients and allows physicians to identify patients expected to have positive outcomes with the Medtronic pain pump.
Medtronic’s evidence-based approach supports oral opioid tapering and drug holidays, enabling to treat with the lowest effective dose of intrathecal medication that will help to improve pain relief compared to a combination of oral and intrathecal treatment.
Developed by clinicians, the evidence-based approach offers comprehensive guidance on therapy initiation, catheter placement and dosing that can result in successful outcomes for sustained pain relief and functional improvement.
Medtronic restorative therapies group’s targeted drug delivery business general manager and vice president Charlie Covert said: “There is a significant unmet need in chronic pain and device-delivered options are underutilized for appropriate patients, so we continue to innovate to maximize the value of proven treatments.
“We rolled out the Control Workflow to help simplify targeted drug delivery therapy, support oral opioid weaning, and offer more patients an effective alternative for pain relief.